Accueil/Actions/CERO

CERO

USD

CERo Therapeutics Holdings Inc. Common Stock

$0.095-0.240 (-71.620%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$0.335

Haut

$0.095

Bas

$0.095

Volume

8.44M

Fondamentaux de l'Entreprise

Capitalisation Boursière

177.4K

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

2.29M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.062Actuel $0.095Haut $896

Actualités Connexes

3 nov. 2025 · 19:07

Analyst Upgrades

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs from Buy to Hold.

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

30 oct. 2025 · 11:48

Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

29 oct. 2025 · 23:22

GlobeNewswire

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

22 oct. 2025 · 12:12

Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

21 oct. 2025 · 12:15

GlobeNewswire

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

GlobeNewswire

15 oct. 2025 · 12:30

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, announces that Chris Ehrlich,